CommercialCoverageMedium impact
Cranial and Auricular Neuromodulation 1.01.58
Excellus BlueCross BlueShield·Pain Management, Neurology, Psychiatry +2 more·Durable Medical Equipment & Supplies
Effective date
May 21, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has classified all cranial and auricular neuromodulation devices as investigational, meaning these treatments will not be covered. This affects devices like Alpha Stim, GammaCore, Cefaly, and various auricular stimulation devices used for pain, ADHD, migraines, and other conditions.
Action Required
Before May 21, 2026: Billing team must identify all patients using cranial or auricular neuromodulation devices (Alpha Stim, GammaCore, Cefaly, P-Stim, IB-Stim, NSS-2 Bridge, Monarch eTNS) and notify them these devices will no longer be covered by Excellus BlueCross BlueShield. Update prior authorization systems to automatically deny coverage for these investigational devices. Providers should discuss alternative covered treatments with affected patients.